conjugated anti-gp240 antibodies (MD Anderson)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameconjugated anti-gp240 antibodies (MD Anderson)
Drug Alias NamescFvMEL/IkappaBalpha (MD Anderson)scfvMEL/rGel constructs (MD Anderson)scFvMEL/TNF (MD Anderson)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionProtein synthesis inhibitors
TargetsUpdating
Therapy Area/IndicationsMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsMelanomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A